CRDF vs CRIS

Cardiff Oncology, Inc. vs Curis, Inc. — Valuation Comparison 2026

CRDF

Biotechnology
Cardiff Oncology, Inc.
Quality
5.9
out of 10
Value Trap
30
LOW
Price
$1.84
Last close
Models
9/13
Active
VS

CRIS

Biotechnology
Curis, Inc.
Quality
5.0
out of 10
Value Trap
39
LOW
Price
$0.52
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CRDF Fair ValueCRDF Upside CRIS Fair ValueCRIS Upside
Bayesian DCF Intrinsic $0.56 -69.7% $0.25 -51.6%
First Chicago Scenario $0.16 -91.1% $0.34 -35.8%
ML-RIV Intrinsic $0.06 -96.2% $0.35 -40.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRDF vs CRIS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRDF vs CRIS — Which Stock Is More Undervalued?

CRDF scores higher with a 5.9/10 quality rating vs CRIS's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cardiff Oncology, Inc. (CRDF) and Curis, Inc. (CRIS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRDF currently trades at $1.84 with a QOC of 5.9/10, while CRIS trades at $0.52 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).